Cue Biopharma is trading 11.5% higher at $17.93, amid a sector-led rally; biotech (XBI) was up 2.1% during the session.

  • No new company-specific announcement explaining the October 20 move surfaced.
  • A Seeking Alpha Buy-rating article about earlier CUE-221 trial results appeared October 20. The results were announced weeks earlier, so the article does not establish a fresh company catalyst.